Closed · RFA-HL-18-035 · CFDA 93.121;93.173;93.233;93.242;93.286;93.350;93.837;93.838;93.839;93.840;93.846;93.847;93.853;93.855;93.856;93.866;93.867 · Discretionary

Regenerative Medicine Innovation Projects (RMIP) (U44 - Clinical Trial Not Allowed)

Federal grant opportunity posted by National Institutes of Health, cataloged on Grants.gov.

up to $225K
Award range
Closed
Status
October 19, 2018
Close date
-
Expected awards

The verdict

Regenerative Medicine Innovation Projects (RMIP) (U44 - Clinical Trial Not Allowed) is a closed discretionary listing from National Institutes of Health that offered Up to $225,000. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 12,419 other opportunities from National Institutes of Health.

up to $225K
award range
Closed
application status
93.121;93.173;93.233;93.242;93.286;93.350;93.837;93.838;93.839;93.840;93.846;93.847;93.853;93.855;93.856;93.866;93.867
CFDA program
12,419
other opportunities from National Institutes of Health

Archived opportunity record

Regenerative Medicine Innovation Projects is closed (last close October 19, 2018). Check the agency catalog for replacement NOFOs. National Institutes of Health still indexes 12,419 other opportunities here.

According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.

Deadline tracker

Application window closed

Closed October 19, 2018

Posted Aug 1 Closes Oct 19

Instrument

Cooperative Agreement

Description

The National Institutes of Health (NIH), participating NIH Institutes and Centers, in coordination with the U.S. Food and Drug Administration, invite cooperative agreement (U44) applications to support small business research studies aimed at furthering the field of regenerative medicine (RM) using adult stem cells. These applications are expected to focus on innovative projects that propose solutions to widely recognized issues in the development of safe and effective RM therapies. Emphasis will be given to projects that address critical issues in product development relevant for regulatory submissions. Areas of focus may include improved tools, methods, standards, or applied science that support a better understanding and improved evaluation of in-depth product characterization, manufacturing, potency, identity, quality, safety, in vivo function and integration, or effectiveness. Toward these ends, the NIH will consider applications for late stage preclinical research studies involving adult stem cells in the context of generating or supplementing the necessary evidence for clinical development, including, but not limited to, the submission of an Investigational New Drug (IND) or Investigational New Device Exemption (IDE) package; or to support such research conducted under an authorized IND or IDE.

Small-business / for-profit corridor · RFA-HL-18-035

Regenerative Medicine Innovation Projects prints a for-profit / small-business applicant door (Small businesses). Treat the listing as business-facing unless the full Grants.gov announcement narrows it further. The extract does not mark applicant cost-sharing as required. Instrument: Cooperative Agreement. Funding-activity codes span Food and Nutrition · Health (FN;HL). 789 other National Institutes of Health listings share this eligibility-code string (6% of 12,420).

Code 23
Small businesses

Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.

Official Listing on Grants.gov

View full details, application forms, and submission instructions.

View on Grants.gov

Agency Contact

NIH OER Webmaster FBOWebmaster@OD.NIH.GOV

More from National Institutes of Health

Closed Closed October 2, 2026

Validation Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U54 Clinical Trials Not Allowed)

View →
Closed Closed October 2, 2026

Logistics Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U24 Clinical Trials Not Allowed)

View →
Closed Closed October 9, 2026

Development and Testing of a Multi-use Frameworks Playbook for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U01 Clinical Trial Not Allowed)

View →
Closed Closed October 19, 2026

PRIMED-AI: Data-to-Model Academic-Industrial Partnerships (D2M-AIP) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (UG3/UH3 Clinical Trial Optional)

View →
Closed Closed October 19, 2026

Model-to-Clinic (M2C) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (UG3/UH3, Clinical Trial Optional)

View →

What to do next

Regenerative Medicine Innovation Projects is closed; use the parent program and agency catalog for the next funding cycle.

  • Browse open federal opportunities in the same category when this listing is closed. Open opportunities
  • Look up CFDA 93.121;93.173;93.233;93.242;93.286;93.350;93.837;93.838;93.839;93.840;93.846;93.847;93.853;93.855;93.856;93.866;93.867 across all indexed listings before you commit to this opportunity alone. Eligibility finder
  • National Institutes of Health lists 12,419 other indexed opportunities on PlainGrants. Agency catalog

Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.

Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.

Read our methodology - how this data is sourced, computed, and verified.

Data sourced from the SAM.gov Assistance Listings and Grants.gov. See our methodology for details. Retrieved and formatted by PlainGrants